Article: CPEX Pharmaceuticals and Serenity Pharmaceuticals Announce Collaboration on Drug Candidate for Urology Indication.

Serenity Files IND for Intranasal Drug Employing CPEX's Delivery Platform

EXETER, N.H. -- CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) and privately held Serenity Pharmaceuticals today announced that they are collaborating on an intranasal drug candidate for a urology indication. New York-based Serenity's drug candidate will be delivered using CPEX's patented drug delivery technology. Serenity believes the drug targets a potential worldwide market of $2 - $3 billion.

The collaboration between Serenity and CPEX began in September 2007 as a feasibility study and advanced to the signing of a development and license agreement in February 2008. Serenity has filed an ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!